Bristol Myers Squibb Reports observational Data for Tezepelumab in Endometrial cancer

Bristol Myers Squibb today announced observational results for tezepelumab in patients with endometrial cancer. The study demonstrated that tezepelumab improves quality of life compared to standard of care or placebo. These results provide important insights into the treatment of endometrial cancer and support the continued development of tezepelumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.